8-K: Disc Medicine Receives Positive FDA Feedback for Bitopertin, Paving Way for Potential Accelerated Approval in EPP

Disc Medicine announced positive feedback from the FDA regarding their end-of-Phase 2 meeting for bitopertin in erythropoietic protoporphyria (EPP), including the potential for accelerated approval.

Summary

• Disc Medicine received positive feedback from the FDA following their end-of-Phase 2 meeting for bitopertin in EPP.
• The FDA agreed with all proposed attributes of the APOLLO study, including the primary endpoint of average monthly time in sunlight without pain.
• The study will be a 6-month, randomized, double-blind, placebo-controlled trial using a 60 mg dose of bitopertin.
• The trial will include patients aged 12 and older with EPP, including XLP.
• The FDA also agreed that a reduction in protoporphyrin IX (PPIX) could serve as a surrogate endpoint to support accelerated approval.
• Disc Medicine plans to initiate the APOLLO trial by mid-2025.
• The company will meet with the FDA to finalize the details of the APOLLO trial and provide an update in the first quarter of 2025.
• The company has the potential to submit a New Drug Application (NDA) based on existing data, with the APOLLO trial serving as a confirmatory trial.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the successful end-of-Phase 2 meeting with the FDA, the agreement on all study parameters, and the potential for accelerated approval. The company has a clear path forward for bitopertin, which is a significant positive development.

Positives

• The FDA agreed with all proposed attributes of the APOLLO study design.
• The primary endpoint of average monthly time in sunlight without pain is considered clinically meaningful.
• The potential for accelerated approval based on existing data and PPIX reduction is a significant advantage.
• The study includes both EPP and XLP patients aged 12 and older.
• The 60 mg dose and 6-month treatment duration were endorsed by the FDA.
• The company has a clear development path to registration for bitopertin.

Risks

• The company's ability to successfully initiate and complete clinical trials is subject to risks and uncertainties.
• The timing of the availability of data from clinical trials is uncertain.
• The results of preclinical and clinical trials may not be predictive of future results.
• The company's ability to obtain regulatory approval for bitopertin is not guaranteed.
• The company's capital may not be adequate to support future operations.

Future Outlook

The company plans to meet with the FDA to finalize the details of the APOLLO trial and provide an update in the first quarter of 2025 on this discussion as well as timing for a potential NDA filing under an accelerated pathway. The APOLLO trial is planned to be initiated by mid-2025.

Management Comments

• John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc, stated that they are thrilled with the outcome of the end-of-Phase 2 meeting with the FDA, which provides a clear development path forward for bitopertin.
• He also mentioned that the FDA agreed with all attributes of the study design, including a primary endpoint they feel is statistically robust.
• He expressed excitement about the potential to file under the Accelerated Approval Program based on existing data and the use of PPIX reduction as a surrogate endpoint.

Industry Context

This announcement is significant as it highlights the potential for a new treatment option for EPP, a rare and debilitating disease with limited treatment options. The accelerated approval pathway could expedite the availability of bitopertin to patients in need. The company is competing with the only other FDA approved treatment, Scenesse (afamelanotide).

Comparison to Industry Standards

• The use of a surrogate endpoint like PPIX reduction for accelerated approval is a common strategy in rare disease drug development, particularly when clinical endpoints are difficult to measure or take a long time to observe.
• The primary endpoint of average monthly time in sunlight without pain is a patient-centric outcome measure that aligns with the goals of EPP treatment.
• The study design, including a randomized, double-blind, placebo-controlled trial, is consistent with industry standards for clinical trials.
• The inclusion of both EPP and XLP patients in the study is a positive step towards addressing the needs of a broader patient population.
• The 60mg dose is consistent with previous studies and is a reasonable dose to move forward with.

Stakeholder Impact

• Shareholders will likely view this news positively due to the potential for accelerated approval and the clear development path for bitopertin.
• Patients with EPP and XLP may benefit from a new treatment option that could improve their quality of life.
• Employees of Disc Medicine may be motivated by the positive progress of the company's lead drug candidate.
• The company's suppliers and partners may see increased business opportunities as the company moves closer to commercialization.

Next Steps

• The company will meet with the FDA to finalize the details of the APOLLO trial.
• The company plans to provide an update in Q1 2025 on the discussion with the FDA and the timing for a potential NDA filing.
• The company plans to initiate the APOLLO trial by mid-2025.
• The company will continue to prepare for commercialization and launch of bitopertin.

Key Dates

Keywords

bitopertin, erythropoietic protoporphyria, EPP, X-linked protoporphyria, XLP, FDA, accelerated approval, APOLLO trial, PPIX, hematologic diseases, clinical trial, surrogate endpoint